GGI
REGN icon

Godsey & Gibb Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Godsey & Gibb Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-130
Closed -$137K – 421
2024
Q3 		$137K Hold
130
– – 0.01% 130
2024
Q2 		$137K Hold
130
– – 0.01% 133
2024
Q1 		$125K Hold
130
– – 0.01% 123
2023
Q4 		$114K Hold
130
– – 0.01% 123
2023
Q3 		$107K Hold
130
– – 0.01% 129
2023
Q2 		$93.4K Hold
130
– – 0.01% 137
2023
Q1 		$107K Hold
130
– – 0.01% 131
2022
Q4 		$93.8K Hold
130
– – 0.02% 90
2022
Q3 		$90K Buy
+130
New +$81.8K 0.07% 24

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Godsey & Gibb Inc's REGN Position: Q4 2024 in Review

Godsey & Gibb Inc sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 130 shares — an estimated $137K sold.

Godsey & Gibb Inc first reported a position in REGN in Q3 2022 and held it in 9 quarters. The position peaked at $137K in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Godsey & Gibb Inc reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Godsey & Gibb Inc sold 130 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $137K.
  • Godsey & Gibb Inc first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 9 quarters.
  • Godsey & Gibb Inc's Regeneron Pharmaceuticals position peaked at $137K in Q3 2024.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Godsey & Gibb Inc's 13F filing for Q4 2024, filed 14 Jan 2025.